Tue, Jul 22, 2014, 8:43 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Alimera Sciences, Inc. (ALIM) Message Board

ilygod 8 posts  |  Last Activity: Jul 18, 2014 10:36 AM Member since: Jan 29, 1999
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    partnerships on the horizon

    by jdoobah Jul 18, 2014 9:37 AM
    ilygod ilygod Jul 18, 2014 10:36 AM Flag

    Placing our bets along with someone who has money, experience, insider knowledge and skin in the game. Let's see how this plays out. I do recall a drug called Imclone that went through several years of ungrade/downgrade cycles. Ultimately, it paid off handsomely.

    The $1 price target is some paid basher of a analyst who obviously has an axe to grind.

    Bid/Ask is tightly controlled by MM. They want to keep things from moving too far to the right or left. I think they will be done soon taking out positions. Then we'll see where they ultimately want to go. How do you think the Shorts cover their positions? The last time there was even a hint, the price quickly spiked to $4.9? Short memory huh?

    I think we'll see movement once options expire tomorrow.

    Have a good weekend.

  • Reply to

    Kovner and his Trust Fund

    by ilygod Jul 16, 2014 6:12 PM
    ilygod ilygod Jul 16, 2014 7:55 PM Flag

    I agree with you. So, with estimate revisions rising among all of the analysts and none revising down, with insiders buying and none selling, with biopharma acquisitions occurring with some frequency, why is there such a large short position on this stock? Who is holding this short position? It certainly is not the retail investors.

    I was first notified of HSP-90 by several of my oncology buddies. Chaperon protein concept is very compelling. So compelling that I believe SNTA's expertise in this arena is worth the acquisition.

    Kovner, while very wealthy, is not throwing money after a loser. His track record speaks very well for itself. If he purchases over 5 million shares around $4, he is very confident that it is worth considerably more. I'd love to see him take this private himself and take it out at a hefty premium. While less likely, this isn't out of the realm of possibilities. If so, he could well be the guy who is playing both sides of SNTA. Conspiracy theory? Why not, right?

  • Bruce could potentially take this private as he owns over 30% of the shares. Or, he could be working towards finding a larger pharma to buy them out.

    I suspect the latter. Since Bruce bought significant number of shares north of $6, I suspect any deal would be at a significant premium from today's price. The price action the last three days is suspect for manipulation to bring the price down before a major announcement. The rise in PPS late last week may have been related someone sniffing out a buyout in the works.

    Then, they come out this week and take the price down to where it all began.

    Time will tell. The science if solid and HSP-90 will have a significant role in battling cancer.

  • ilygod ilygod Jun 27, 2014 4:40 PM Flag

    Correction over 34 million shares = over $120 million dollars of Synta.

  • Sounds like Buyout here. Kovner already owns over a billion dollars worth of this stock. I think this is a buyout offer being seriously weighed. Shorts may have won the week but I think the billionaire will have the last laugh.

  • FDA approved product. Adoption will increase. DSCO will be bought out. FMR and Broadfin are believers. At this price, 30% returns should be a no brainer.

  • Spherix acquires over 100 patents, patent applications portfolio from Rockstar
    Spherix announced that it has entered into a series of agreements with Rockstar Consortium in which Spherix Incorporated acquired over 100 patents and patent applications. The newly acquired patents cover among other things, numerous aspects of access, switching, routing, optical and voice communication network devices. Spherix Incorporated, through its wholly owned subsidiary, Spherix Portfolio Acquisition II entered into its second agreement to acquire certain patents from Rockstar Consortium US LP. The company acquired a suite of 101 patents pursuant to a Patent Purchase Agreement in several technology families, including data, optical and voice technology. The patents provide the company rights to develop and commercialize products as well as enforcement rights for past, present and future infringement. The company issued $60M of its securities at an issuance price of $8.35 per share of common stock for the Rockstar Patents. Additionally, Rockstar is entitled to a participation in future recoveries under the Rockstar Patents after the company receives 100% return on the value of the issued Securities.

  • GIMO growth is sustainable. International sales will propel this company. At this price, this looks like a juicy takeover. This is what the analysts are seeing and slapping a PT of $30!

6.02+0.26(+4.51%)Jul 22 4:00 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Puma Biotechnology, Inc.
NYSETue, Jul 22, 2014 4:01 PM EDT
Microsoft Corporation
NasdaqGSTue, Jul 22, 2014 4:00 PM EDT